Silence Therapeutics plc Share-based Payment Arrangement, Expense
Silence Therapeutics plc (SLNCF) reported Share-based Payment Arrangement, Expense of $8.07 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-03-05
- Silence Therapeutics plc share-based payment arrangement, expense for fiscal 2025 was $8.07M, a 50.49% decline from fiscal 2024.
- Silence Therapeutics plc share-based payment arrangement, expense for fiscal 2024 was $16.31M, a 0.20% increase from fiscal 2023.
- Silence Therapeutics plc share-based payment arrangement, expense for fiscal 2023 was $16.27M, a 28.28% increase from fiscal 2022.
- Silence Therapeutics plc share-based payment arrangement, expense for fiscal 2022 was $12.69M.
| Period end | Share-based Payment Arrangement, Expense 12 month |
|---|---|
| 2025-12-31 | $8.07M 10-K · filed 2026-03-05 |
| 2024-12-31 | $16.31M 10-K · filed 2026-03-05 |
| 2023-12-31 | $16.27M 10-K · filed 2025-02-27 |
| 2022-12-31 | $12.69M 10-K · filed 2025-02-27 |